Ipilimumab, marketed under the brand name Yervoy, is a type of immunotherapy known as a checkpoint inhibitor. It works by blocking the CTLA-4 protein, which helps keep the immune system from attacking cancer cells. By blocking CTLA-4, Yervoy enhances the body's immune response against cancer cells [1].

When comparing Yervoy to other immunotherapies, it is important to consider the type of cancer being treated, the patient's overall health, and the potential side effects. Yervoy is approved by the FDA for the treatment of melanoma, renal cell carcinoma, and colorectal cancer [1].

In terms of efficacy, Yervoy has been shown to improve overall survival in patients with advanced melanoma when compared to traditional chemotherapy [2]. However, its response rates can be lower than other immunotherapies such as PD-1 inhibitors, such as nivolumab (Opdivo) and pembrolizumab (Keytruda) [3].

When comparing the safety profile of Yervoy to other immunotherapies, it is important to note that Yervoy can cause severe and potentially life-threatening side effects, such as immune-mediated colitis, hepatitis, and dermatitis [1]. On the other hand, PD-1 inhibitors have been associated with a lower incidence of severe side effects [3].

In terms of cost, Yervoy is one of the most expensive cancer drugs on the market, with a list price of approximately $120,000 for a typical course of treatment [4]. Other immunotherapies, such as nivolumab and pembrolizumab, have similar list prices [4].

In conclusion, Yervoy is an effective immunotherapy for the treatment of certain types of cancer, but its response rates and side effect profile may differ from other immunotherapies. Additionally, its high cost should be taken into consideration when comparing it to other treatment options.

Sources:

1. [Yervoy (ipilimumab) prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125287s023s024lbl.pdf)
2. Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., ... & Chin, L. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363(8), 711-723.
3. Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., ... & Daud, A. (2015). Nivolumab in previously untreated melanoma without BRAF mutation. New England Journal of Medicine, 372(4), 323-334.
4. [DrugPatentWatch.com](https://www.drugpatentwatch.com/drugs/yervoy)
5. [Specialty Drug Pricing and Trends](https://www.express-scripts.com/corporate/static/uploads/2019-Specialty-Drug-Trends-Report.pdf)